Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer

Details

Serval ID
serval:BIB_C1E386784977
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer
Journal
Therapeutic Drug Monitoring
Author(s)
Blaser  J., Konig  C., Fatio  R., Follath  F., Cometta  A., Glauser  M.
ISSN
0163-4356 (Print)
Publication state
Published
Issued date
04/1995
Volume
17
Number
2
Pages
133-6
Notes
Clinical Trial
Journal Article
Multicenter Study --- Old month value: Apr
Abstract
During once-daily dosing regimens of aminoglycosides, administration of large single doses results in high peak levels and low 24-h trough levels. However, commercial assays for monitoring aminoglycoside levels are designed to cover the smaller range of serum concentrations usually observed during multiple daily dosing regimens. The study assessed (a) the range of serum concentrations during once-daily dosing of amikacin and (b) the performance of a widely used assay system for measuring concentrations within this range. A total of 42 dosing intervals from eight patients receiving a once-daily regimen of amikacin (20 mg/kg) were monitored. Median (and range) of peak, 8- and 24-h trough levels were 61 (25-89), 5.9 (2.2-19), and 1.3 (< 0.8-6.2) mg/L, respectively. The accuracy of a fluorescence polarization immunoassay for measuring concentrations of amikacin during once-daily dosing regimens was assessed in an international multicenter study. The performance of the assay was excellent for peak and 8-h concentrations; median deviations from the target concentrations were < 5%. The majority of the trough levels (26 of 42) measured in patients during once-daily treatment were within the range of 1-2 mg/L and could also be determined with an accuracy sufficient for clinical monitoring (median deviations 14%).
Keywords
Adult Amikacin/blood/*pharmacokinetics Creatinine/blood Dosage Forms *Drug Monitoring Humans Middle Aged Quality Control Time Factors
Pubmed
Web of science
Create date
25/01/2008 13:31
Last modification date
20/08/2019 15:36
Usage data